FDA update on CBD offers no timetable for action

FDA update on CBD offers no timetable for action

FDA says it will soon reopen the docket for comments on how it should regulate hemp-derived cannabidiol (CBD) and is considering a “risk-based enforcement policy” to address concerns about the proliferation of CBD products, but the agency still lacks a timetable for when it might lay out a regulatory pathway for foods or supplements that contain the non-psychoactive cannabis ingredient.

https://iegpolicy.agribusinessintelligence.informa.com/PL223276/FDA-update-on-CBD-offers-no-timetable-for-action

Industry News